CING Cingulate Inc.

NASDAQ
$4.83

Cingulate Inc. (CING) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.48 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.6% since its last earnings release on August 13, 2026.

Cingulate Beat Consensus Estimates
Thursday, August 13, 2026 · 8:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 8:30 AM ET
Earnings Whisper
-
vs ($0.48)
Rev est $2.68M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.27

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.